CAH Cardinal Health, Inc. Common Stock
NYSE · Health Care · Wyświetl na SEC EDGAR ↗ zamknij Paź 5, 2026 10-K/10-Q Sie 11, 2026CAH Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
CAH Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 23 kwietnia 2001 | 3-for-2 | Naprzód |
| 2 listopada 1998 | 3-for-2 | Naprzód |
| 17 grudnia 1996 | 3-for-2 | Naprzód |
| 1 lipca 1994 | 5-for-4 | Naprzód |
| 1 października 1991 | 5-for-4 | Naprzód |
| 1 października 1990 | 5-for-4 | Naprzód |
| 2 października 1989 | 5-for-4 | Naprzód |
| 9 września 1988 | 11-for-10 | Naprzód |
| 9 września 1987 | 11-for-10 | Naprzód |
O Cardinal Health, Inc. Common Stock Przegląd firmy z Wikipedii
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | CAH | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E | 32.9średnia z 5 lat ≈29.4 | ≈29.4 | 22.9 | Zawyżona wycena | |
| PEG Ratio (Współczynnik PEG) | ≈1.2 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | CAH | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża brutto (TTM) | 3.8%średnia z 5 lat ≈3.5% | ≈3.5% | 4.3% | Słaby | |
| Marża Operacyjna (TTM) | 1.0%średnia z 5 lat ≈0.52% | ≈0.52% | 1.1% | Zgodnie z | |
| Marża EBITDA (TTM) | 1.4%średnia z 5 lat ≈0.88% | ≈0.88% | 1.3% | Zgodnie z | |
| Marża przed opodatkowaniem (TTM) | 0.86%średnia z 5 lat ≈0.44% | ≈0.44% | 1.0% | Poniżej średniej | |
| Marża Zysku Netto (TTM) | 0.67%średnia z 5 lat ≈0.27% | ≈0.27% | 0.63% | Zgodnie z | |
| ROA | 3.1%średnia z 5 lat ≈1.3% | ≈1.3% | 3.1% | Zgodnie z | |
| ROE | -60.5%średnia z 5 lat ≈-65.5% | ≈-65.5% | -4.6% | Słaby | |
| ROIC | -71.1%średnia z 5 lat ≈-13.6% | ≈-13.6% | 12.2% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | CAH | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Wskaźnik bieżący (MRQ) | 0.9średnia z 5 lat ≈1.0 | ≈1.0 | 0.9 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 0.4średnia z 5 lat ≈0.5 | ≈0.5 | 0.5 | Niska płynność | |
| Interest Coverage (Pokrycie odsetek) | 7.5średnia z 5 lat ≈9.3 | ≈9.3 | 5.9 | Silna płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | CAH | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 14.2%średnia z 5 lat ≈9.5% | ≈9.5% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 7.4%średnia z 5 lat ≈9.1% | ≈9.1% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 9.4% | · | · | · | |
| EPS YoY | 12.1%średnia z 5 lat ≈91.0% | ≈91.0% | · | · | |
| Net Income YoY (Zysk Netto R/R) | 9.8%średnia z 5 lat ≈83.7% | ≈83.7% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 79.0% | · | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | 28.3% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 73.2% | · | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | 22.9% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | CAH | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 4.6średnia z 5 lat ≈4.6 | ≈4.6 | 4.5 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 14.3średnia z 5 lat ≈13.2 | ≈13.2 | 15.7 | Słaby | |
| Receivables Turnover (Rotacja należności) | 18.8średnia z 5 lat ≈18.6 | ≈18.6 | 13.1 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$4.3M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Paź 1, 2026 | $0,52 | USD | ≈0.89% |
| Lip 1, 2026 | $0,52 | USD | ≈0.86% |
| Kwi 1, 2026 | $0,51 | USD | ≈0.96% |
| Sty 2, 2026 | $0,51 | USD | ≈0.99% |
| Paź 1, 2025 | $0,51 | USD | ≈1.3% |
| Lip 1, 2025 | $0,51 | USD | ≈1.2% |
| Kwi 1, 2025 | $0,51 | USD | ≈1.5% |
| Sty 2, 2025 | $0,51 | USD | ≈1.7% |
| Paź 1, 2024 | $0,51 | USD | ≈1.8% |
| Lip 1, 2024 | $0,51 | USD | ≈2.1% |
| Mar 28, 2024 | $0,50 | USD | ≈1.8% |
| Gru 29, 2023 | $0,50 | USD | ≈2.0% |
| Paź 2, 2023 | $0,50 | USD | ≈2.3% |
| Cze 30, 2023 | $0,50 | USD | ≈2.1% |
| Mar 31, 2023 | $0,50 | USD | ≈2.6% |
| Gru 30, 2022 | $0,50 | USD | ≈2.6% |
| Wrz 30, 2022 | $0,50 | USD | ≈3.0% |
| Cze 30, 2022 | $0,50 | USD | ≈3.8% |
| Mar 31, 2022 | $0,49 | USD | ≈3.5% |
| Gru 31, 2021 | $0,49 | USD | ≈3.8% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 31 grudnia 2026 | Sie 11, 2026 | $2.91 | $2.44 | 19.1% |
| 30 czerwca 2026 | $2.60 | $2.44 | 6.4% | |
| 31 marca 2026 | $3.17 | $2.82 | 12.6% | |
| 31 grudnia 2025 | $2.63 | $2.40 | 9.4% | |
| 30 września 2025 | $2.55 | $2.20 | 15.9% | |
| 30 czerwca 2025 | $2.08 | $2.06 | 1.1% | |
| 31 marca 2025 | $2.35 | $2.19 | 7.4% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
Bilans
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
Przepływy pieniężne
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
Rentowność
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
Efektywność
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
Na akcję
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $1072.78 | $919.74 | $918.33 | $782.49 | $650.05 | $552.61 | $521.92 | $483.50 | $434.31 | $406.18 | $368.32 | $306.06 | |
| Cash Flow / Share | $21.83 | $9.90 | $15.23 | $10.84 | $11.19 | $8.26 | $6.69 | $9.04 | $8.79 | $3.70 | $9.00 | $7.58 | |
| Dividend Paid / Share | $2.04 | $2.02 | $2.00 | $1.98 | $1.96 | $1.94 | $1.92 | $1.91 | $1.85 | $1.80 | $1.55 | $1.37 | |
| EPS (TTM) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 |
Stopy Wzrostu
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
Rachunek zysków i strat
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | · | 235,000,000 | 236,000,000 | 238,000,000 | · | 240,000,000 | 242,000,000 | 243,000,000 | · | 243,000,000 | 245,000,000 | 249,000,000 | · | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | · | 236,000,000 | 237,000,000 | 239,000,000 | · | 241,000,000 | 243,000,000 | 245,000,000 | · | 245,000,000 | 246,000,000 | 249,000,000 | · | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
Bilans
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
Przepływy pieniężne
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
Rentowność
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
Efektywność
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
Na akcję
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $258.22 | $276.91 | $267.82 | · | $227.71 | $227.42 | $213.38 | · | $224.13 | $233.52 | $219.05 | · | $195.69 | $197.20 | $181.70 | |
| Cash Flow / Share | · | · | · | $4.07 | · | · | · | $-6.72 | · | · | · | $2.18 | · | · | · | $0.08 | |
| Dividend / Share | · | $0.51 | $0.51 | $0.51 | · | $0.51 | $0.51 | $0.51 | · | $0.50 | $0.50 | $0.50 | · | $0.50 | $0.50 | $0.50 |
Wycena (TTM)
| Wskaźnik | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $250.74B | $244.67B | $234.31B | · | $222.29B | $222.28B | $224.45B | · | $220.38B | $216.01B | $210.04B | · | $198.62B | $192.96B | $186.95B | |
| Net Income TTM | · | $1.55B | $1.66B | $1.59B | · | $1.56B | $1.31B | $1.28B | · | $622M | $726M | $281M | · | $519M | $-1.24B | $-1.11B | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% | |
| Annual Payout | · | $491M | $495M | $495M | · | $496M | $494M | $496M | · | $503M | $509M | $514M | · | $533M | $541M | $552M |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Przychody | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| Marża Brutto % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| Marża Operacyjna % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| Zysk netto | $1.71B | $1.56B | $852M | $330M | $-938M |
| Rozwodniony EPS | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
| Wskaźnik | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| Wskaźnik Szybkości | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
| Wskaźnik | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
Właściciele instytucjonalni (13F) 1 605 emitentów · $54.4B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 156 (-26 vs poprzedni kw.) | 81 (-19 vs poprzedni kw.) | 530 (-24 vs poprzedni kw.) | 574 (+58 vs poprzedni kw.) | +7.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6 461 178 523 | 31 441 258 | 11,88% | Akcje |
| BlackRock, Inc. | $6 293 114 912 | 26 490 633 | 11,57% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $3 632 811 706 | 15 292 186 | 6,68% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $3 530 205 977 | 14 860 271 | 6,49% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3 258 822 899 | 13 717 894 | 5,99% | Akcje |
| STATE STREET CORP | $2 842 909 265 | 11 967 121 | 5,23% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $1 531 751 894 | 6 472 810 | 2,82% | Akcje |
| Invesco Ltd. | $1 126 646 236 | 4 742 576 | 2,07% | Akcje |
| MORGAN STANLEY | $1 098 793 649 | 4 625 329 | 2,02% | Akcje |
| WCM INVESTMENT MANAGEMENT, LLC | $971 445 537 | 4 112 461 | 1,79% | Akcje |
| NORGES BANK | $885 248 810 | 3 726 422 | 1,63% | Akcje |
| BANK OF AMERICA CORP /DE/ | $689 065 528 | 2 900 596 | 1,27% | Akcje |
| NORTHERN TRUST CORP | $681 536 598 | 2 868 903 | 1,25% | Akcje |
| JPMORGAN CHASE & CO | $630 412 357 | 2 668 749 | 1,16% | Akcje |
| GOLDMAN SACHS GROUP INC | $566 588 458 | 2 385 033 | 1,04% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $499 624 076 | 2 103 149 | 0,92% | Akcje |
| FMR LLC | $490 857 853 | 2 066 248 | 0,90% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $490 754 373 | 2 322 438 | 0,90% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $469 793 667 | 1 977 579 | 0,86% | Akcje |
| Legal & General Group Plc | $438 869 762 | 1 847 406 | 0,81% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $411 645 774 | 1 732 808 | 0,76% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $369 172 278 | 1 554 017 | 0,68% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $315 702 986 | 1 328 940 | 0,58% | Akcje |
| AMERIPRISE FINANCIAL INC | $311 391 613 | 1 310 794 | 0,57% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $308 748 216 | 1 297 534 | 0,57% | Akcje |
| Bank of New York Mellon Corp | $308 639 982 | 1 299 209 | 0,57% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $281 612 012 | 1 185 468 | 0,52% | Akcje |
| Robeco Institutional Asset Management B.V. | $258 918 781 | 1 089 909 | 0,48% | Akcje |
| DEUTSCHE BANK AG\ | $238 933 097 | 1 005 780 | 0,44% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $230 523 823 | 970 390 | 0,42% | Akcje |
| JANE STREET GROUP, LLC | $225 610 732 | 949 700 | 0,41% | Opcja sprzedaży |
| Man Group plc | $222 013 123 | 934 556 | 0,41% | Akcje |
| WELLS FARGO & COMPANY/MN | $219 711 690 | 924 868 | 0,40% | Akcje |
| UBS Group AG | $218 780 954 | 920 950 | 0,40% | Akcje |
| Amundi | $211 809 683 | 891 605 | 0,39% | Akcje |
| Nuveen, LLC | $211 731 009 | 891 274 | 0,39% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $203 800 043 | 857 888 | 0,37% | Akcje |
| ProShare Advisors LLC | $197 187 154 | 830 052 | 0,36% | Akcje |
| ROYAL BANK OF CANADA | $185 518 000 | 780 931 | 0,34% | Akcje |
| BARCLAYS PLC | $177 344 480 | 746 525 | 0,33% | Akcje |
| FEDERATED HERMES, INC. | $176 399 992 | 742 549 | 0,32% | Akcje |
| SEI INVESTMENTS CO | $173 413 944 | 729 965 | 0,32% | Akcje |
| JANE STREET GROUP, LLC | $169 712 864 | 714 400 | 0,31% | Opcja kupna |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $163 869 121 | 693 714 | 0,30% | Akcje |
| Allianz Asset Management GmbH | $163 833 492 | 689 651 | 0,30% | Akcje |
| Swedbank AB | $159 718 953 | 672 331 | 0,29% | Akcje |
| Swiss National Bank | $157 644 816 | 663 600 | 0,29% | Akcje |
| JANUS HENDERSON GROUP PLC | $155 390 858 | 735 467 | 0,29% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141 722 832 | 596 577 | 0,26% | Akcje |
| 1832 Asset Management L.P. | $139 039 117 | 585 280 | 0,26% | Akcje |
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 zgłoszenia | 5 czerwca 2014 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 2 lipca 2004 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 28 maja 2004 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 84 insiderów · 45 dyrektorzy generalni · 37 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jason M. Hollar | Chief Executive Officer | 19 sierpnia 2026 S | 190 603 | 0 | 10 | $-29 375 516 |
| Deborah Weitzman | CEO, PSS Segment | 18 sierpnia 2026 S | 77 901 | 0 | 3 | $-1 731 524 |
| Stephen M Mason | CEO, GMPD Segment | 18 sierpnia 2026 S | 18 061 | 0 | 4 | $-8 274 118 |
| Michael C Kaufmann | CEO | 15 sierpnia 2022 M | 601 065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | 15 sierpnia 2022 F | 105 699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | 15 sierpnia 2019 F | 61 387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | 15 września 2017 F | 146 503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | 27 lutego 2012 M | 89 204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | 1 września 2009 A | 238 635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | 2 września 2007 F | 68 041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | 16 maja 2006 M | 36 082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | 13 grudnia 2004 A | 14 400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | 18 sierpnia 2026 S | 20 495 | 0 | 5 | $-10 451 104 |
| Jorge M Gomez | Chief Financial Officer | 8 listopada 2018 F | 39 582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | 27 sierpnia 2014 M | 67 190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | 17 listopada 2003 A | · | 0 | 0 | $0 |
| George L Fotiades | President & COO | 15 stycznia 2003 P | 80 278 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | 19 sierpnia 2026 S | 2 811 | 0 | 2 | $-546 473 |
| Michelle D. Greene | Chief Information Officer | 18 sierpnia 2026 S | 10 330 | 0 | 6 | $-3 373 574 |
| Jessica L Mayer | Chief Legal/Compliance Officer | 18 sierpnia 2026 S | 33 076 | 0 | 4 | $-6 952 485 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 15 sierpnia 2026 F | 11 757 | 0 | 0 | $0 |
| Ola M Snow | Chief Human Resources Officer | 1 grudnia 2025 F | 15 111 | 0 | 0 | $0 |
| Patricia M English | Chief Accounting Officer | 15 sierpnia 2022 F | 9 000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | 15 sierpnia 2022 F | 37 850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | 15 sierpnia 2022 F | 44 491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | 15 sierpnia 2020 F | 12 289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | 3 grudnia 2018 F | 126 301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | 31 sierpnia 2018 F | 30 725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | 15 sierpnia 2018 F | 22 612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | 15 sierpnia 2018 F | 502 630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | 20 maja 2016 M | 31 585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | 30 listopada 2015 G | 32 455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | 17 listopada 2015 F | 16 760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | 7 listopada 2014 M | 20 409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | 1 listopada 2008 F | 50 886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | 26 września 2008 A | 39 594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | 26 listopada 2007 I | 1 740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | 4 czerwca 2007 M | 8 573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | 2 września 2006 F | 85 978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | 6 września 2005 G | 55 382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | 2 września 2005 A | 6 137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | 2 września 2005 A | 4 607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | 17 lutego 2005 G | 7 000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | 23 sierpnia 2004 A | 2 462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | 24 lutego 2004 M | 31 039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | Dyrektor | 15 kwietnia 2026 A | 28 645 | 0 | 1 | $-918 880 |
| Michelle Brennan | Dyrektor | 5 listopada 2025 A | 8 086 | 0 | 0 | $0 |
| Robert Azelby | Dyrektor | 5 listopada 2025 A | 4 085 | 0 | 0 | $0 |
| Nancy Killefer | Dyrektor | 5 listopada 2025 A | 27 624 | 0 | 0 | $0 |
| Akhil Johri | Dyrektor | 5 listopada 2025 A | 22 868 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | Dyrektor | 5 listopada 2025 A | 2 116 | 0 | 0 | $0 |
| Sheri H. Edison | Dyrektor | 5 listopada 2025 A | 14 848 | 0 | 0 | $0 |
| Christine Mundkur | Dyrektor | 5 listopada 2025 A | 7 536 | 0 | 0 | $0 |
| Gregory B Kenny | Dyrektor | 5 listopada 2025 A | 64 194 | 0 | 0 | $0 |
| Steven Barg | Dyrektor | 15 listopada 2023 A | 4 739 | 0 | 0 | $0 |
| Sujatha Chandrasekaran | Dyrektor | 15 listopada 2023 A | 4 739 | 0 | 0 | $0 |
| Bruce Downey | Dyrektor | 9 listopada 2022 A | 53 929 | 0 | 0 | $0 |
| COX CARRIE SMITH | Dyrektor | 9 listopada 2022 A | 41 631 | 0 | 0 | $0 |
| Dean A Scarborough | Dyrektor | 18 października 2022 A | 11 138 | 0 | 0 | $0 |
| John H Weiland | Dyrektor | 11 listopada 2021 A | 11 138 | 0 | 0 | $0 |
| Michael J Losh | Dyrektor | 15 października 2021 A | 9 988 | 0 | 0 | $0 |
| Calvin Darden | Dyrektor | 9 listopada 2020 A | 39 616 | 0 | 0 | $0 |
| Colleen F. Arnold | Dyrektor | 12 listopada 2019 A | 35 103 | 0 | 0 | $0 |
| David J Anderson | Dyrektor | 16 stycznia 2018 A | 9 946 | 0 | 0 | $0 |
| David P King | Dyrektor | 8 listopada 2017 A | 21 044 | 0 | 0 | $0 |
| Clayton M Jones | Dyrektor | 8 maja 2017 S | 0 | 0 | 0 | $0 |
| NOTEBAERT RICHARD C | Dyrektor | 3 marca 2015 M | 35 778 | 0 | 0 | $0 |
| John F Finn | Dyrektor | 5 listopada 2014 A | 21 074 | 0 | 0 | $0 |
| Glenn Britt | Dyrektor | 7 maja 2014 A | 18 314 | 0 | 0 | $0 |
| Jean G Spaulding | Dyrektor | 6 listopada 2013 A | 17 182 | 0 | 0 | $0 |
| David W Raisbeck | Dyrektor | 2 listopada 2011 A | 17 075 | 0 | 0 | $0 |
| James J Mongan MD | Dyrektor | 3 listopada 2010 A | 7 150 | 0 | 0 | $0 |
| Philip L Francis | Dyrektor | 1 września 2009 D | 1 021 | 0 | 0 | $0 |
| John B Mccoy | Dyrektor | 5 listopada 2008 A | 2 721 | 0 | 0 | $0 |
| Robert D Walter | Dyrektor | 6 października 2008 M | 1 531 235 | 0 | 0 | $0 |
| Matthew D Walter | Dyrektor | 7 stycznia 2008 G | 2 232 | 0 | 0 | $0 |
| Robert L Gerbig | Dyrektor | 12 lutego 2007 M | 66 218 | 0 | 0 | $0 |
| John F Havens | Dyrektor | 8 listopada 2006 A | 30 973 | 0 | 0 | $0 |
| David Bing | Dyrektor | 3 sierpnia 2005 A | 3 669 | 0 | 0 | $0 |
| Robert W Musslewhite | · | 5 listopada 2025 A | 2 116 | 0 | 0 | $0 |
| David C Evans | · | 5 listopada 2025 A | 15 373 | 0 | 0 | $0 |
| David L Schlotterbeck | · | 1 września 2009 D | 61 523 | 0 | 0 | $0 |
| Michael D Ohalleran | · | 1 września 2009 D | 8 458 | 0 | 0 | $0 |
| George N Conrades | · | 5 listopada 2008 A | 2 653 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 148 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PEZ · Invesco Exchange-Traded Fund Trust | 5,29% | 4 961 SH | 2 października 2026 | Dziennie |
| FXG · First Trust Exchange-Traded AlphaDE… | 3,15% | 31 414 NS | 31 lipca 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 2,97% | 12 009 NS | 31 lipca 2026 | N-PORT |
| IYK · iShares Trust | 2,56% | 150 019 SH | 11 września 2026 | Dziennie |
| NUMV · Nushares ETF Trust | 2,30% | 44 435 NS | 31 lipca 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 2,09% | 14 948 SH | 2 października 2026 | Dziennie |
| SMRI · EA Series Trust | 1,84% | 51 638 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,59% | 59 923 SH | 2 października 2026 | Dziennie |
| NULV · Nushares ETF Trust | 1,53% | 145 860 NS | 31 lipca 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,51% | 597 NS | 31 lipca 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,49% | 228 600 NS | 31 lipca 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,47% | 1 193 309 NS | 31 lipca 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 1,34% | 23 570 SH | 19 sierpnia 2026 | Dziennie |
| UPSD · ETF Series Solutions | 1,31% | 6 646 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 1,25% | 527 725 SH | 2 października 2026 | Dziennie |
| SRHQ · Elevation Series Trust | 1,20% | 11 056 NS | 31 lipca 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 1,11% | 6 347 SH | 2 października 2026 | Dziennie |
| RPV · Invesco Exchange-Traded Fund Trust | 1,10% | 79 806 SH | 2 października 2026 | Dziennie |
| ESMV · iShares Trust | 1,06% | 350 SH | 11 września 2026 | Dziennie |
| PDP · Invesco Exchange-Traded Fund Trust | 1,06% | 67 986 SH | 2 października 2026 | Dziennie |
| VOE · VANGUARD INDEX FUNDS | 0,96% | 1 504 470 SH | 19 sierpnia 2026 | Dziennie |
| ABFL · Abacus FCF ETF Trust | 0,92% | 21 099 NS | 31 lipca 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,87% | 4 124 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,82% | 707 389 SH | 19 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 111 939 NS | 31 lipca 2026 | N-PORT |
| IWP · iShares Trust | 0,74% | 604 324 SH | 11 września 2026 | Dziennie |
| LSEQ · Harbor ETF Trust | 0,70% | 468 NS | 31 lipca 2026 | N-PORT |
| IXJ · iShares Trust | 0,70% | 123 272 SH | 11 września 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,62% | 4 609 NS | 31 lipca 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,59% | 4 662 NS | 31 lipca 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,55% | 31 604 NS | 31 lipca 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,54% | 5 075 476 SH | 19 sierpnia 2026 | Dziennie |
| FTLS · First Trust Exchange-Traded Fund III | 0,51% | 54 815 NS | 31 lipca 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,47% | 19 654 SH | 2 października 2026 | Dziennie |
| LGDX · Tidal Trust III | 0,44% | 2 735 NS | 31 lipca 2026 | N-PORT |
| EVUS · iShares Trust | 0,43% | 6 970 SH | 11 września 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,43% | 108 869 NS | 31 lipca 2026 | N-PORT |
| IMCG · iShares Trust | 0,42% | 71 722 SH | 11 września 2026 | Dziennie |
| QLC · FlexShares Trust | 0,42% | 18 368 NS | 31 lipca 2026 | N-PORT |
| IWR · iShares Trust | 0,41% | 959 539 SH | 11 września 2026 | Dziennie |
| LCOW · Pacer Funds Trust | 0,40% | 454 NS | 31 lipca 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,39% | 11 919 NS | 31 lipca 2026 | N-PORT |
| IMCB · iShares Trust | 0,39% | 27 470 SH | 11 września 2026 | Dziennie |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 7 324 NS | 31 lipca 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,36% | 5 200 NS | 31 lipca 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 7 082 NS | 31 lipca 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,35% | 445 000 | 2 października 2026 | Dziennie |
| IMCV · iShares Trust | 0,35% | 16 989 SH | 11 września 2026 | Dziennie |
| ACWV · iShares, Inc. | 0,33% | 46 363 SH | 11 września 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,32% | 9 479 000 | 2 października 2026 | Dziennie |
| XOEF · iShares Trust | 0,31% | 293 SH | 11 września 2026 | Dziennie |
| IWS · iShares Trust | 0,29% | 189 265 SH | 11 września 2026 | Dziennie |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,28% | 30 714 NS | 31 lipca 2026 | N-PORT |
| GLOF · iShares Trust | 0,28% | 2 389 SH | 11 września 2026 | Dziennie |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,28% | 12 847 000 | 2 października 2026 | Dziennie |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,27% | 6 869 NS | 31 lipca 2026 | N-PORT |
| ESGU · iShares Trust | 0,26% | 200 383 SH | 11 września 2026 | Dziennie |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,26% | 17 795 NS | 31 lipca 2026 | N-PORT |
| NULC · Nushares ETF Trust | 0,26% | 796 NS | 31 lipca 2026 | N-PORT |
| CATH · Global X Funds | 0,26% | 14 490 NS | 31 lipca 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0,25% | 7 970 000 | 2 października 2026 | Dziennie |
| DYNF · BlackRock ETF Trust | 0,25% | 443 705 SH | 11 września 2026 | Dziennie |
| VFMO · VANGUARD WELLINGTON FUND | 0,25% | 21 158 SH | 19 sierpnia 2026 | Dziennie |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,24% | 1 323 136 SH | 19 sierpnia 2026 | Dziennie |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,23% | 233 192 SH | 2 października 2026 | Dziennie |
| VYM · VANGUARD WHITEHALL FUNDS | 0,23% | 934 496 SH | 19 sierpnia 2026 | Dziennie |
| ESG · FlexShares Trust | 0,23% | 1 320 NS | 31 lipca 2026 | N-PORT |
| SIZE · iShares Trust | 0,22% | 3 988 SH | 11 września 2026 | Dziennie |
| LRGF · iShares Trust | 0,22% | 33 556 SH | 11 września 2026 | Dziennie |
| VTV · VANGUARD INDEX FUNDS | 0,21% | 2 225 442 SH | 19 sierpnia 2026 | Dziennie |
| VFMF · VANGUARD WELLINGTON FUND | 0,21% | 6 281 SH | 19 sierpnia 2026 | Dziennie |
| EUSA · iShares, Inc. | 0,20% | 16 612 SH | 11 września 2026 | Dziennie |
| PFM · Invesco Exchange-Traded Fund Trust | 0,20% | 6 670 SH | 2 października 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 813 183 SH | 2 października 2026 | Dziennie |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,19% | 53 931 SH | 19 sierpnia 2026 | Dziennie |
| IVE · iShares Trust | 0,19% | 388 621 SH | 11 września 2026 | Dziennie |
| IUSV · iShares Trust | 0,18% | 205 310 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,18% | 6 098 SH | 2 października 2026 | Dziennie |
| IQSU · New York Life Investments ETF Trust | 0,17% | 2 435 NS | 31 lipca 2026 | N-PORT |
| CHRI · Global X Funds | 0,16% | 57 NS | 31 lipca 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,16% | 4 467 000 | 2 października 2026 | Dziennie |
| DSI · iShares Trust | 0,16% | 35 796 SH | 11 września 2026 | Dziennie |
| EGLE · Global X Funds | 0,13% | 12 NS | 31 lipca 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,12% | 6 NS | 31 lipca 2026 | N-PORT |
| LQAI · Exchange Listed Funds Trust | 0,12% | 12 NS | 31 lipca 2026 | N-PORT |
| DGRO · iShares Trust | 0,12% | 217 268 SH | 11 września 2026 | Dziennie |
| VFVA · VANGUARD WELLINGTON FUND | 0,11% | 3 797 SH | 19 sierpnia 2026 | Dziennie |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,10% | 7 530 SH | 2 października 2026 | Dziennie |
| TOPC · iShares Trust | 0,10% | 144 SH | 11 września 2026 | Dziennie |
| ACVF · ETF Opportunities Trust | 0,10% | 675 NS | 31 lipca 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,10% | 52 911 SH | 19 sierpnia 2026 | Dziennie |
| DFSU · Dimensional ETF Trust | 0,10% | 9 417 NS | 31 lipca 2026 | N-PORT |
| ILCG · iShares Trust | 0,10% | 12 549 SH | 11 września 2026 | Dziennie |
| XVV · iShares Trust | 0,09% | 2 689 SH | 11 września 2026 | Dziennie |
| USMV · iShares Trust | 0,09% | 91 385 SH | 11 września 2026 | Dziennie |
| VOO · VANGUARD INDEX FUNDS | 0,09% | 6 082 026 SH | 19 sierpnia 2026 | Dziennie |
| VV · VANGUARD INDEX FUNDS | 0,09% | 273 537 SH | 19 sierpnia 2026 | Dziennie |
| XRMI · Global X Funds | 0,09% | 194 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,09% | 244 NS | 31 lipca 2026 | N-PORT |
| XYLD · Global X Funds | 0,09% | 12 239 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,08% | 45 685 NS | 31 lipca 2026 | N-PORT |
| IVV · iShares Trust | 0,08% | 2 952 119 SH | 11 września 2026 | Dziennie |
| PTLC · Pacer Funds Trust | 0,08% | 11 916 NS | 31 lipca 2026 | N-PORT |
| XCLR · Global X Funds | 0,08% | 13 NS | 31 lipca 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 32 252 NS | 31 lipca 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,08% | 21 NS | 31 lipca 2026 | N-PORT |
| ILCB · iShares Trust | 0,08% | 4 535 SH | 11 września 2026 | Dziennie |
| VOTE · TCW ETF Trust | 0,08% | 3 959 NS | 31 lipca 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,08% | 1 385 SH | 2 października 2026 | Dziennie |
| BKLC · BNY Mellon ETF Trust | 0,08% | 19 424 NS | 31 lipca 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,08% | 40 564 SH | 2 października 2026 | Dziennie |
| XTR · Global X Funds | 0,08% | 17 NS | 31 lipca 2026 | N-PORT |
| IWD · iShares Trust | 0,08% | 282 063 SH | 11 września 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,08% | 7 436 156 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,08% | 38 624 SH | 19 sierpnia 2026 | Dziennie |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,08% | 76 610 SH | 19 sierpnia 2026 | Dziennie |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 169 890 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,08% | 19 715 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,08% | 913 NS | 31 lipca 2026 | N-PORT |
| IWB · iShares Trust | 0,08% | 162 672 SH | 11 września 2026 | Dziennie |
| IYY · iShares Trust | 0,08% | 10 064 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,08% | 71 472 NS | 31 lipca 2026 | N-PORT |
| USCL · iShares Trust | 0,08% | 9 352 SH | 11 września 2026 | Dziennie |
| SPUU · Direxion Shares ETF Trust | 0,08% | 884 NS | 31 lipca 2026 | N-PORT |
| IWF · iShares Trust | 0,08% | 402 774 SH | 11 września 2026 | Dziennie |
| QDPL · Pacer Funds Trust | 0,08% | 5 627 NS | 31 lipca 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,08% | 32 168 SH | 2 października 2026 | Dziennie |
| IWV · iShares Trust | 0,08% | 64 328 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,08% | 304 905 SH | 11 września 2026 | Dziennie |
| ILCV · iShares Trust | 0,07% | 4 083 SH | 11 września 2026 | Dziennie |
| TILT · FlexShares Trust | 0,07% | 6 802 NS | 31 lipca 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,07% | 183 SH | 2 października 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,07% | 9 717 NS | 31 lipca 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,07% | 1 627 NS | 31 lipca 2026 | N-PORT |
| TOK · iShares Trust | 0,07% | 656 SH | 11 września 2026 | Dziennie |
| SPXL · Direxion Shares ETF Trust | 0,06% | 18 311 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,06% | 129 668 NS | 31 lipca 2026 | N-PORT |
| URTH · iShares, Inc. | 0,06% | 20 873 SH | 11 września 2026 | Dziennie |
| ACWI · iShares Trust | 0,05% | 74 784 SH | 11 września 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,05% | 197 885 SH | 19 sierpnia 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,01% | 343 NS | 31 lipca 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 40 400 | 30 września 2026 | Dziennie |
| GTOS · Invesco Actively Managed Exchange-T… | 0,00% | 600 | 30 września 2026 | Dziennie |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
CAH Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
15 analityków · 2026-10-02Średnia cel $270.33 +16,0%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CAH | · | 32.9 | 14.2% | 0.67% | -60.5% | 3.8% |
| MCK | $242.30B | 22.5 | 12.4% | 1.2% | -224.3% | 3.6% |
| COR | $60.61B | 39.3 | 9.3% | 0.48% | 144.3% | 3.6% |
| HSIC | $8.81B | 23.3 | 4.0% | 3.0% | 12.0% | 31.1% |
| AHCO | $1.35B | -19.2 | -0.49% | -2.2% | -4.6% | · |
| ACH | · | · | · | · | · | · |
| MEDS | · | · | · | · | · | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.